Development of an effective, noninvasive colorectal cancer screening test has long been a priority. Although fecal DNA testing has shown potential in preliminary studies, the current report is the ...

A groundbreaking blood test for colorectal cancer screening could reshape early detection. Learn how this FDA-approved method ...

In this study, the performance characteristics of the immunochemical test were superior to those of the Hemoccult II guaiac-based test. Note, however, that Hemoccult II is less sensitive than the ...

Regular fecal occult blood test (FOBT) screening for colorectal cancer is cost-effective in the general population, yet data are limited regarding the cost-effectiveness of FOBT screening in renal ...

Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and ...

The fecal immunochemical test, also known as FIT, is used to screen for colorectal cancer. The FIT is performed the same way as the traditional fecal occult blood test without the need to follow a ...

The company hopes that its noninvasive assay is easier to use than stool-based fecal occult blood tests (FOBTs), currently the mainstay for early detection, but it does not see it replacing ...

Under the agreement, Sysmex will distribute and service in Canada Sentinel Diagnostics' SentiFit 270 and SentiFit 800 analyzers for fecal immunochemical testing.